THE UNIVERSITY OF MARYLAND CENTER OF EXCELLENCE IN REGULATORY SCIENCE AND INNOVATION, IN COLLABORATION WITH THE U.S. FOOD AND DRUG ADMINISTRATION, PRESENTS:

PEDIATRIC ONTOGENY: READY FOR INCORPORATION INTO MODELING IN PEDIATRIC DRUG DEVELOPMENT?



CONFERENCE AGENDA

THURSDAY, MAY 16, 2019

MODERATORS:

- Gilbert J. Burckart, PharmD Associate Director for Pediatrics Office of Clinical Pharmacology Food and Drug Administration
- Jian Wang, PhD Associate Director for Regulatory Science Office of Drug Evaluation IV Office of New Drugs

AGENDA:

Тіме	
8:00-8:35 a.m.	
8:35-8:55 a.m.	
8:55-9:15 a.m.	
9:15-9:35 a.m.	

Center for Drug Evaluation and Research Food and Drug Administration

 Jill Morgan, PharmD, BCPS, BCPPS Professor and Chair Department of Pharmacy Practice and Science University of Maryland School of Pharmacy

ACTIVITY

INTRODUCTION

WELCOME / PEDIATRIC DRUG DEVELOPMENT Gilbert J. Burckart, PharmD Associate Director for Pediatrics Office of Clinical Pharmacology Food and Drug Administration

DEVELOPMENTAL PHARMACOKINETICS

John van den Anker, MD, PhD Pediatric Clinical Pharmacology Children's National Medical Center

DEVELOPMENTAL PHARMACODYNAMICS

Greg Kearns, PharmD, PhD President Arkansas Children's Research Institute

MODELING AND SIMULATION USING PEDIATRIC ONTOGENY INFORMATION

Stefan Willmann, PhD Clinical Pharmacometrics Research & Development Bayer

	Drug Metabolism and Transporter Function
9:35-10:00 a.m.	ONTOGENY AND PHASE II METABOLISM OF DRUGS Stephan Schmidt, PhD Associate Professor Center for Pharmacometrics and Systems Pharmacology University of Florida
10:00-10:20 a.m.	Вгеак
10:20-10:45 a.m.	ONTOGENY OF PHASE I METABOLISM OF DRUGS Steve Leeder, PharmD, PhD Marion Merrell Dow Endowed Chair in Pediatric Precision Therapeutics Mercy Children's Hospital
10:45-11:10 a.m.	ONTOGENY OF DRUG TRANSPORTER FUNCTION Shiew Mei Huang, PhD Deputy Directory, Office of Clinical Pharmacology Center for Drug Evaluation and Research Food and Drug Administration
11:10 a.m Noon	MODERATED PANEL DISCUSSION Moderators: Drs. Burckart and Morgan
	Panelists : Drs. van den Anker, Kearns, Huang, Leeder, Willmann, Edress Darsey (Pfizer), and Sander Vinks (University of Cincinnati)
Noon – 1 p.m.	LUNCH
	RENAL FUNCTION, PHARMACOGENOMICS ONTOGENY
1:00-1:25 p.m.	ONTOGENY OF RENAL FUNCTION AND RENAL DRUG ELIMINATION Jian Wang, PhD Associate Director, Regulatory Science Office of Drug Evaluation IV Office of New Drugs Food and Drug Administration
1:25-1:50 p.m.	ONTOGENY AND APPLICATION OF PHARMACOGENOMICS TO PEDIATRICS Dionna Green, MD Deputy Director, Office of Pediatric Therapeutics Commissioner's Office Food and Drug Administration
	APPLICATIONS TO PEDIATRIC DRUG DEVELOPMENT
1:50-2:20 p.m.	APPLICATION OF ONTOGENY WITHIN MIDD FOR PEDIATRICS Hao Zhu, PhD Deputy Director, Division of Pharmacometrics Office of Clinical Pharmacology Center for Drug Evaluation Food and Drug Administration
2:20-2:40 p.m.	Вкеак



THANKS TO PROGRAM COMMITTEE MEMBERS:

- Gil Burckart (FDA)
- Jian Wang (FDA)
- Jill Morgan (University of Maryland)
- John van den Anker (Children's National, Washington D.C.)
- Andre Dallmann (Bayer)
- Dionna Green (FDA)
- Sander Vinks (University of Cincinnati)
- George Giacoia (NIH)